Theravance (THRX) - FREE Research Report

Glaxosmithkline Plc who is 10% Owner at Theravance bought 342,229 shares at $12,850,698.95 on Feb. 13, 2014. Following this transaction, the 10% Owner owned 30.3 million shares meaning that the stake was reduced by 1.14% with the 342,229-share transaction.

The shares most recently traded at $39.61, down $12,850,659.34, or 32442967.28% since the insider transaction. Historical insider transactions for Theravance go as follows:

  • 12-Week # shares sold: 22,353
  • 24-Week # shares sold: 22,353

The average volume for Theravance has been 946,700 shares per day over the past 30 days. Theravance has a market cap of $4.2 billion and is part of the health care sector and drugs industry. Shares are up 7.91% year-to-date as of the close of trading on Thursday.

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines primarily for therapeutic areas of respiratory diseases, bacterial infections, and central nervous system (CNS)/pain. Currently there are 5 analysts that rate Theravance a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on THRX - FREE

TheStreet Quant Ratings rates Theravance as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Theravance Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Unearth This New Relic Trade

Symantec CEO Clark Not Ruling Out Another Deal

3 Reasonably Valued Tech Stocks That Are Worth a Look

3 Reasonably Valued Enterprise Tech Stocks That Are Worth a Look